• A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

  NCT06382987

  RecruitingObservationalUpdated Apr 25, 2024
• A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

  NCT06104644

  Active, not recruitingObservationalUpdated Dec 4, 2025
• A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

  NCT05744466

  RecruitingObservationalUpdated Jul 23, 2024
• A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

  NCT06512337

  Active, not recruitingObservationalUpdated Apr 15, 2026
• A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

  NCT05701995

  CompletedInterventionalPhase 4Updated Jun 3, 2026
• A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

  NCT05633264

  CompletedObservationalUpdated Jul 3, 2025

ClinicalTrials.gov ID

NCT06701513

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

350Estimated

Last Update Posted

May 18, 2026Actual

Start Date

Jan 29, 2025Actual

Primary Completion Date

Apr 30, 2028Estimated

Completion Date

Apr 30, 2028Estimated

Official Title

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France

Brief Summary

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

• Psoriasis

• Deucravacitinib

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No data available

Eligibility Criteria

Inclusion Criteria:

• ≥18 years of age
• Physician-reported diagnosis of moderate to severe plaque psoriasis
• Be newly initiating deucravacitinib
• Do not object to participate

Exclusion Criteria:

• Currently participating in or planning to participate in an interventional clinical trial
• Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Bristol-Myers SquibbINDUSTRY

33 3 80 29 33 36

+33492036225